Chemoprevention of Lung Cancer

Department of Medicine, VA Eastern Colorado Healthcare System, University of Colorado at Denver Health Sciences Center, Denver, Colorado 80220, USA.
Proceedings of the American Thoracic Society 05/2009; 6(2):187-93. DOI: 10.1513/pats.200807-067LC
Source: PubMed


Lung cancer is the leading cause of cancer death in the United States, and the majority of diagnoses are made in former smokers. While avoidance of tobacco abuse and smoking cessation clearly will have the greatest impact on lung cancer development, effective chemoprevention could prove to be more effective than treatment of established disease. Chemoprevention is the use of dietary or pharmaceutical agents to reverse or inhibit the carcinogenic process and has been successfully applied to common malignancies other than lung. Despite previous studies in lung cancer chemoprevention failing to identify effective agents, our ability to determine higher risk populations and the understanding of lung tumor and pre-malignant biology continues to advance. Additional biomarkers of risk continue to be investigated and validated. The World Health Organization/International Association for the Study of Lung Cancer classification for lung cancer now recognizes distinct histologic lesions that can be reproducibly graded as precursors of non-small cell lung cancer. For example, carcinogenesis in the bronchial epithelium starts with normal epithelium and progresses through hyperplasia, metaplasia, dysplasia, and carcinoma in situ to invasive squamous cell cancer. Similar precursor lesions exist for adenocarcinoma, and these pre-malignant lesions are targeted by chemopreventive agents in current and future trials. At this time, chemopreventive agents can only be recommended as part of well-designed clinical trials, and multiple trials are currently in progress and additional trials are in the planning stages. This review will discuss the principles of chemoprevention, summarize the completed trials, and discuss ongoing and potential future trials with a focus on targeted pathways.

Full-text preview

Available from:
  • Source
    • "Although lung cancers often present late, there are many possible avenues for intervention within both a surgical and chemopreventive context. Primary chemoprevention focuses on preventing the development of precancerous lesions particularly in high-risk populations, such as smokers; secondary prevention aims to prevent progression of preneoplasia to cancer; and tertiary prevention is concerned with prevention of spread or recurrence of primary disease (Keith, 2009). Early disease can be classified into papillomas (squamous, glandular, or mixed) and adenomas (alveolar, papillary, salivarygland-type ). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is responsible for over 1 million deaths worldwide each year. Smoking cessation for lung cancer prevention remains key, but it is increasingly acknowledged that prevention strategies also need to focus on high risk groups including ex-smokers, and patients who have undergone resection of a primary tumor. Models for chemoprevention of lung cancer often present conflicting results, making rational design of lung cancer chemoprevention trials challenging. There has been much focus on use of dietary bioactive compounds in lung cancer prevention strategies, primarily due to their favorable toxicity profile and long history of use within the human populace. One such compound is curcumin, derived from the spice turmeric. This review summarises and stratifies pre-clinical evidence for chemopreventive efficacy of curcumin in models of lung cancer, and adjudges the weight of evidence for use of curcumin in lung cancer chemoprevention strategies.
    Journal of Pharmacology and Experimental Therapeutics 06/2014; 350(3). DOI:10.1124/jpet.114.216333 · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the leading cause of cancer death in the world. In the United States, lung cancer causes more death per annum than colorectal, breast, and prostate cancers combined. While smoking prevention and cessation are essential strategies against lung cancer, they are often ineffective, and former smokers remain at lower, yet persistent risks. The magnitude of the tobacco epidemic and burden of lung cancer will continue to escalate globally, underscoring the importance of advancing chemoprevention research. Recently, exciting results from phase 2b randomized control trials are beginning to emerge. Advancements in understanding clinical tumor biology, diagnostic technology, and bioinformatics will continue to propel significant progress in the field. This update will provide a general overview of the background and rationale for lung cancer chemoprevention, review important results from historical trials, summarize key findings from recently completed studies, and discuss ongoing clinical trials and future directions for lung cancer chemoprevention.
    03/2012; 1(1). DOI:10.1007/s13665-011-0004-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Phase 0 trials can provide proof of concept that an agent modulates its intended target without exposing patients to the drug-tolerability testing that precedes efficacy evaluation. Drugs that do not modulate their targets can be discarded, focusing development resources on the most clinically promising agents. However, wider uptake of Phase 0 trials may be hindered by ethical concerns over their lack of therapeutic intent, the substantial resources required to develop and validate target assays or skepticism that such trials save development time.
    Future medicinal chemistry 11/2009; 1(8):1375-80. DOI:10.4155/fmc.09.117 · 3.74 Impact Factor
Show more